Antibody targets under evaluation in lung cancer clinical trials include: cMET, DLL/Notch, FGF/FGF-R, HER2, mesothelin, PDGFR-alpha, TROP2, and lastly EGFR and VEGF/VEGF-R, whose respective targeting antibodies necitumumab and bevacizumab, have been approved for subsets of patients with advanced NSCLC, including as a first-line therapy (102–106). This evidence concerns the gene MSLN and lung cancer.